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Abstract
Heterozygous glucokinase (GCK) mutations cause a subtype of maturity-onset diabetes of the young (GCK-MODY). Over 600
GCK mutations have been reported of which ,65% are missense. In many cases co-segregation has not been established
and despite the importance of functional studies in ascribing pathogenicity for missense variants these have only been
performed for ,10% of mutations. The aim of this study was to determine the minimum prevalence of GCK-MODY amongst
diabetic subjects in Slovakia by sequencing GCK in 100 Slovakian probands with a phenotype consistent with GCK-MODY
and to explore the pathogenicity of identified variants through family and functional studies. Twenty-two mutations were
identified in 36 families (17 missense) of which 7 (I110N, V200A, N204D, G258R, F419S, c.580-2A.C, c.1113–1114delGC)
were novel. Parental DNA was available for 22 probands (covering 14/22 mutations) and co-segregation established in all
cases. Bioinformatic analysis predicted all missense mutations to be damaging. Nine (I110N, V200A, N204D, G223S, G258R,
F419S, V244G, L315H, I436N) mutations were functionally evaluated. Basic kinetic analysis explained pathogenicity for 7
mutants which showed reduced glucokinase activity with relative activity indices (RAI) between 0.6 to ,0.001 compared to
wild-type GCK (1.0). For the remaining 2 mutants additional molecular mechanisms were investigated. Differences in
glucokinase regulatory protein (GKRP) –mediated-inhibition of GCK were observed for both L315H & I436N when compared
to wild type (IC50 14.660.1 mM & 20.361.6 mM vs.13.360.1 mM respectively [p,0.03]). Protein instability as assessed by
thermal lability studies demonstrated that both L315H and I436N show marked thermal instability compared to wild-type
GCK (RAI at 55uC 8.860.8% & 3.160.4% vs. 42.563.9% respectively [p,0.001]). The minimum prevalence of GCK-MODY
amongst Slovakian patients with diabetes was 0.03%. In conclusion, we have identified 22 GCK mutations in 36 Slovakian
probands and demonstrate that combining family, bioinformatic and functional studies can aid the interpretation of
variants identified by molecular diagnostic screening.
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Introduction
Heterozygous inactivating mutations in the glucokinase gene
(GCK) are one cause of maturity-onset diabetes of the young
(MODY) characterized by stable elevated fasting plasma glucose
levels [1,2]. Micro and macrovascular complications are rare and
patients can usually be treated by diet modification alone [3]. A
molecular diagnosis is important because there are implications for
treatment, prognosis and family members [3]. The prevalence of
GCK-MODY is difficult to assess as the mild hyperglycaemia and
absence of symptoms mean that many patients are not diagnosed.
Large scale population based studies have not been performed but
a number of studies have ascertained the prevalence of GCK-
MODY in subjects with impaired glucose tolerance and diabetes
[4,5,6,7,8,9,10,11]. There are differences in prevalence across
these studies which likely reflect both the age of the population
tested and the ascertainment criteria [12,13,14].
Glucokinase is a key enzyme in glycolysis which has been
termed the pancreatic glucose sensor on account of its kinetic
properties which result in the threshold for glucose stimulated
insulin release (GSIR) being around 5 mmol/L [15]. Heterozy-
gous inactivating GCK mutations shift the set point for GSIR,
resulting in elevated fasting plasma glucose levels (typically
between 5.5–8.0 mmol/L in individuals with GCK mutations
[16,17]). The majority of individuals with GCK-MODY have a
small (,3.5 mmol/L) 2 hour glucose increment following an oral
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34541glucose tolerance test (OGTT) which can help distinguish them
from patients with other forms of MODY [18].
Over 600 GCK mutations have been reported and in a recent
review by Osbak and colleagues over 65% (402/620) are missense,
with 56% only been reported in a single family [12]. There is
increasing recognition of the difficulties in ascribing pathogenicity
to missense variants uncovered through medical resequencing
projects. Despite the importance of establishing co-segregation this
is often over looked and functional studies have only been
performed for a minority (,10%) of missense mutations [12]. A
recent study has highlighted the importance of using a combina-
tion of approaches to correctly assign pathogenicity for GCK
missense mutations [19]. In this study, we report an investigation
of the minimum prevalence of GCK-MODY in Slovakia followed
by an exploration of the pathogenicity of identified variants
through family, bioinformatic and functional studies.
Materials and Methods
Subjects
One hundred probands collected between years 2003–2010
underwent diagnostic screening for GCK mutations following
referral from their diabetologist. Selection criteria for testing were
persistent and stable fasting hyperglycemia (5.5–10.0 mmol/L),
HbA1c,8% [64 mmol/ml] (DCCT scale), age of diagnosis ,35
years, and where on insulin treatment, the dose was ,0.4 IU/Kg/
day. Informed written consent was obtained from all subjects. For
subjects under the age of 18 years written consent was obtained
from either a parent or legal guardian.
Mutation Screening
Genomic DNA was extracted from peripheral blood using the
Flexi Gene kit (Qiagen Ltd, Crawley, UK). The GCK neuroen-
docrine promoter, exons 1a and 2–10, and all intron-exon
boundaries were amplified by PCR using previously published
primers [20], and sequenced bi-directionally. Sequences were
compared to the reference genomic GCK sequence
(NM_000162.3) using SeqScape (version 2.1.1; Applied Biosys-
tems). Partial or entire GCK deletions were excluded by multiplex
ligation-dependent probe amplification (MLPA) using the P241-B
MODY kit (MRC-Holland, Amsterdam, The Netherlands).
Results were analyzed using GeneMarker version 1.95 (Soft
Genetics, State College, PA, USA).
Phenotypic characterisation
Plasma glucose concentrations were measured via the glucose
oxidase method (Hitachi 911, Hitachinaka, Japan), whilst
cholesterol, HDL-cholesterol and triglyceride levels were mea-
sured using standard enzymatic protocols (Diasys diagnostic
systems, Holzheim, Germany; Randox Laboratories Ltd. Crumlin,
UK).
In silico structural analysis
All missense mutations were analysed in silico using SIFT,
PolyPhen, and Mutation Taster (http://sift.jcvi.org/, http://
genetics.bwh.harvard.edu/pph/ and http://www.mutationtaster.
org/ respectively). Three-dimensional stuctural analysis was
performed using PyMOL version 1.2 (DeLano Scientific, South
San Francisco, CA, USA).
Preparation of recombinant proteins
Two preparations of human wild-type and each GCK mutant
were generated as recombinant gluthationyl S-transferase-tagged
fusion proteins using previously-described protocols [21,22,23].
Recombinant human wild-type glucokinase regulatory protein
(GKRP) was also prepared as previously published [24,25].
Enzyme kinetics
The kinetic properties of each GCK enzyme were determined
using glucose 6-phosphate dehydrogenase-coupled assays [21,22].
The relative activity index (RAI) for each enzyme and the
predicted threshold for glucose stimulated insulin release (GSIR)
were calculated as previously described [17]. Inhibition assays with
human GKRP were performed in line with previous studies
[24,25,26].
Thermolability Assays
Thermal instability assays were carried-out using previously
described protocols [22,27], but with the following modifications.
Each GCK enzyme was incubated over a 40–63uC temperature
range for 30 minutes. Immediately after incubation, enzymes were
diluted in an assay containing 100 mmol/L HEPES, 6 mmol/L
MgCl2, 150 mmol/L KCl, 2 mmol/L DTT(prior to GCK activity
measurement) [22,28,29].
GCK-MODY frequency data
The minimum prevalence of GCK-MODY in Slovakia was
calculated based on available data for the total number of diabetic
patients, and the total number of inhabitants in Slovakia based on
the Slovak National Health Information Center (NCZI, www.
nczisk.sk).
Statistical Analysis
Continuous variables are reported as mean plus or minus the
standard error of the mean (SEM). Comparisons amongst
variables were carried out using independent sample t-tests on
SPSS software (version 17.0, IBM, Chicago, IL, USA). Incon-
tinous variables are reported as median with a given range.
Results
GCK mutational screening and clinical characterisation
Mutational screening identified 22 GCK mutations in 36 of the
probands (Table 1); 17 missense, 1 frame-shift, 2 in frame
deletions, 1 promoter and 1 splice-site. Seven of these mutations
were novel (I110N, V200A, N204D, G258R, F419S, c.580-
2A.C, c.1113-1114delGC), they were also absent from 200
control chromosomes from normoglycaemic individuals. No
variants were present in the October 2011 release of the 1000
Genomes project (http://www.1000genomes.org/). All novel
mutations except G258R were identified in a single family, whilst
G258R was identified in 2 unrelated families. Parental DNA was
available for 22 probands (covering 14/22 mutations) and co-
segregation was established in all cases (Figure S1). No partial or
whole GCK deletions were identified. The clinical and biochemical
characteristics of the GCK mutation carriers are presented in
table 2. The median proband age is consistent with other studies
which have evaluated diabetes subtype [30].
In silico analysis of all missense mutations
In silico analysis of all missense mutations was performed using a
suite of bioinformatic tools. Analysis in SIFT, PolyPhen and
Mutation Taster revealed that for the majority of mutations there
was consensus between the different bioinformatic tools but for 4
mutations (R43H, V200A, G223S, V244G) at least one program
did not predict a clear impact on protein function (Table S1).
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kinetic evaluation.
Kinetic Characterisation
The basic kinetic profiles of recombinant wild type and the
mutant GCK proteins are given in table 3. Seven of the nine
mutant proteins (I110N, V200A, N204D, G223S, V244G,
G258R, F419S) were shown to be kinetically inactivating, with a
decreased rate of catalysis (Kcat) and/or a decreased affinity for
glucose (increased S0.5). Of note G258R-GCK and N204D-GKC
had extremely low affinities for glucose, with S0.5 values of
.1000 mmol/L. Interestingly, I110N had an increased affinity for
ATP, but was still calculated as being kinetically inactivating as the
mutant enzyme had a very low Kcat. Two mutant enzymes,
L315H-GCK and I436N-GCK displayed near-normal kinetics,
with similar glucose affinities, Hill number (nH), Kcat, and only a
marginally decreased affinity for ATP, compared with the wild-
type enzyme.
To elucidate the molecular mechanism for these two mutants
exhibiting near-normal kinetics (L315H and I436N), their
interaction with the endogenous hepatic regulator GKRP and
their effect on protein stability were explored. Both L315H-GCK
and I436N-GCK demonstrated an impaired response to GKRP-
mediated inhibition compared with wild-type GCK (Figure 1).
Accordingly, the IC50 values for both mutants were slightly but
significantly elevated (14.660.1 mmol/L for I436N,
20.361.6 mmol/L for L315H, and13.360.1 mmol/L for wild-
type [both p-values,0.03]).
Thermal instability assays
To explore whether protein instability could contribute to the
mutational mechanism behind the I436N and L315H mutations,
thermal-lability assays were performed over a 40–63uC temper-
ature range for both mutant proteins and the known instability
mutant E300K-GCK [31]. Analysis of these data showed that
both L315H-GCK and I436N-GCK demonstrated marked
thermal instability compared to wild-type GCK (Figure 2). The
relative activity indices of both mutant enzymes was greatly
reduced at 55uC, with values of 8.860.8% and 3.160.4%
respectively compared to 42.563.9% for wild-type GCK
[p,0.001].
Structural analysis
To understand the extremely low rate of catalysis for N204D-
GCK and G258R-GCK we investigated the impact of these
mutations on the structure of glucokinase. Modeling established
that both residues G258 and N204 are located in close proximity
to the glucose binding site. Mutation of residue G258 from glycine
to arginine results in obstruction of the glucose binding pocket
(Figure S2). Structural analysis of the N204 residue revealed that
mutation from asparagine to arginine cause a gain of one extra
polar bond with residue N254 which is located in the neighboring
beta sheet (Figure S2).
Minimum prevalence of GCK-MODY in Slovakia
GCK mutations were identified in 36 of the 100 probands
screened and mutation testing in family members identified a
Table 1. GCK mutations identified in Slovakian probands with a phenotype of GCK-MODY.
Region
Abbreviated protein
nomenclature Nucleotide nomenclature
Number of probands
with mutation
Reported functional
studies References
Islet promoter - c.271G.C 9 Y [42]
exon 2 R36W c.106C.T 1 Y [43]
exon 2 R43H c.128G.A 1 N [35]
exon 3 G72R c.214G.A 1 Y [44,45]
exon 3 I110N c.329T.A 1 - Novel
exon 4 F150del c.449–451delTCT 1 N [8,45]
exon 4 S151del c.451–453delTCC 1 N [44]
exon 5 A188T c.562G.A 1 Y [46]
intron 5 - c.580 -2A.C 1 - Novel
exon 6 V200A c.599C.T 1 - Novel
exon 6 N204D c.610A.G 1 - Novel
exon 6 T206P c.616A.C 1 N [12]
exon 6 G223S c.667G.A 1 N [8,44]
exon 7 T228M c.683C.T 1 N [47]
exon 7 V244G c.731T.G 2 N [12]
exon 7 M251I c.752T.G1 N[ 8 ]
exon 7 G258R c.772G.C 2 - Novel
exon 8 L315H c.944T.A 2 N [48]
exon 8 G318R c.352G.A3 N[ 4 ]
exon 9 A370fs c.1113–1114delCG 1 - Novel
exon 10 F419S c.1256T.C 1 - Novel
exon 10 I436N c.1307A.T 2 N [48]
All sequence information is based on GenBank reference sequence NM_000162.3. Nucleotide numbering reflects cDNA position, with +1 corresponding to the A of the
major start codon of exon 1a (present in the pancreatic isoform). Y=yes, N=no.
doi:10.1371/journal.pone.0034541.t001
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with diabetes in Slovakia (Slovak National Health Information
Center, 2010), and GCK-MODY confirmed in 108 individuals,
this represents 0.03% of all diabetic patients. Recalculated to the
number of inhabitants in Slovakia (5.4M, Slovak National Health
Information Center, 2008), the minimum prevalence of the GCK-
MODY is estimated to be 20.0 cases per million.
Table 2. Clinical and biochemical parameters of Slovakian GCK mutation carriers.
Probands with GCK
mutations Family members with GCK mutations
n=36 n=72
Number data available
on
Age of diabetes diagnosis (yr) 11.0 (4–45) 26.5 (5–81) 40
$
Age at investigation (yr) 16.5 (4–47) 35.0 (1–86) 72
BMI (kg/m
2) 19.6 (14.3–29.3) 23.4 (15.2–47.4) 44
HbA1c (%) 6.4 (5.1–7.7) * 6.5 (5.0–9.7) 16
Fasting plasma glucose (mmol/L) 6.9 (5.5–9.8) 7.0 (5.2–11.8) 65
Cholesterol (mmol/L) 4.1 (3.0–5.9) 4.5 (3.0–7.3) 64
Triglycerides (mmol/L) 0.8 (0.3–2.4) * 0.9 (0.2–10.0) 64
HDL-cholesterol (mmol/L) 1.2 (0.5–2.0)
# 1.1 (0.6–2.1) 64
Treatment before GCK-MODY diagnosis 42
-insulin (%) 19.4 11.9
-OHA (%) 16.7 23.8
-diet (%) 52.8 42.9
-none (%) 11.1 21.4
Treatment following GCK-MODY diagnosis 42
-insulin (%) 2.8 2.4
-OHA (%) 5.5 14.3
-diet (%) 80.6 61.9
-none (%) 11.1 21.4
Data are presented as median values (range).
*Data only available for 35 probands.
#Data only available for 33 probands.
$For the remaining 32 subjects, diabetes/impaired glucose tolerance was not detected prior to genetic testing.
BMI=body mass index, HbA1c=glycated hemoglobin A1c, HDL=High Density Lipoprotein, OHA=oral hypoglyceamic agents.
doi:10.1371/journal.pone.0034541.t002
Table 3. Kinetic characterisation of GCK-MODY mutations.
GCK-GST S0.5 [mmol/L] Hill number
ATPKm [mmol/L] Kcat S0.5 [s
21] Relative Activity Index (RAI)
WT 7.6960.10 1.6760.01 0.4460.01 65.7860.84 1
I110N 14.8760.25 1.3760.03 0.036,0.01 3.0760.04 0.02
V200A** 78.360.97 1.2860.01 0.6960.07 56.8560.81 0.01
N204D NO NO 5.4260.10 NO NO
V244G* 12.7760.33 1.5260.02 0.460.01 75.7161.36 0.43
G258R NO NO NO NO NO
G223S 16.560.16 1.4660.02 0.4760.01 74.4561.63 0.25
L315H 8.0960.06 1.6760.01 0.5060.01 69.2160.63 0.89
F419S
# 161.5061.64 1.1260.01 6.1460.23 82.1060.80 ,0.01
I436N 7.8460.25 1.6660.02 0.5060.03 73.7760.73 1.07
Data are given as mean 6SEM measured in n$12 experiments. GCK-GST enzymes were prepared as 3 (WT)/2 (G258R)/1 (others) independent protein expressions.
Glucose S0.5 values were normally measured in the glucose range 0–100 mmol/L with 5 mmol/L ATP, however for some mutant enzymes the glucose range was
increased to 0–300 mmol/L (*), 0–600 mmol/L (**), or 0–1000 mmol/L with 25 mmol/L ATP (
#).
NO=data not obtainable due to the severity of the kinetic inactivation which prevented the data from reaching a plateau even with a 10-fold increase in glucose
concentration.
doi:10.1371/journal.pone.0034541.t003
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It is important to identify patients with GCK-MODY as the
diagnosis affects clinical management, prognosis and has implica-
tions for family members. We have screened 100 Slovakian
probands with a phenotype consistent with GCK-MODY and
identified variants in 36% (36/100) of cases. The majority (77%),
of variants are missense and a recent study has highlighted the
importance of using a combination of family, bioinformatic and
functional studies to correctly assign pathogeneticy [19].
Parental DNA was available for 22 of the probands covering 14
of the 22 mutations and co-segregation was established in all cases.
In two families there were individuals with diabetes who were not
mutation carriers (Figure S1). Clinical data supports these
individuals as having type 2 diabetes (phenocopies) rather than
GCK-MODY (details given in Figure S1). A suite of
bioinformatic tools (SIFT, PolyPhen, Mutation Taster) were used
to assess the impact of all missense variants on protein function.
These analyses included conservation of amino acid residues
across species (SIFT, Mutation Taster), change in protein structure
and function (PolyPhen, Mutation Taster) and effects on splicing
or mRNA expression (Mutation Taster) [32,33,34]. SIFT and
PolyPhen gave similar results predicting the vast majority of
mutations to be damaging or possibly damaging (R43H, G223S)
and predicting one mutation (V200A) to be tolerated. In contrast
the newer program Mutation Taster predicted all mutations to be
damaging.
Although bioinformatic prediction softwares are a useful tool
the gold standard in assigning pathogenicity to mutations is to
demonstrate genetic evidence (i.e. co-segregation in families) and
an impact on protein function. Establishing co-segregation for late
on-set disorders can be difficult due to problems in correctly
assigning affection status and incomplete penetrance. However,
with GCK-MODY the assignment of affection status is facilitated
by a phenotype (raised fasting plasma glucose) which is easy to
measure and presents from birth. Despite this it can still be difficult
within a clinical setting to recruit family members for testing. We
were able to test parental DNA for 22 of the 36 probands, which
Figure 1. Inhibition of wild type, I436N and L315H glucokinase proteins by human GKRP. Data are shown as mean 6SEM, and were
obtained from 4 independent measurements. Independent t-tests were used to ascertain differences between GKRP-mediated inhibition of both
mutants versus that obtained with the wild-type GCK enzyme.
doi:10.1371/journal.pone.0034541.g001
Figure 2. Assessment of thermostability for GCK-GST mutant proteins. Proteins were incubated for 30 minutes over a range of
temperatures (40–60uC). Given data are means 6SEM, and were obtained from 6 independent measurements. The previously reported thermal
instability mutant E300K [31](pink) was used as a positive control. The level of significance at each temperature point (mutants versus wild-type GCK
activity) was calculated using an independent t-test.
doi:10.1371/journal.pone.0034541.g002
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cases. Importantly this included all novel mutations and those with
ambiguous in silico predictions. To complement our genetic and in
silico studies we selected all novel missense mutations and those for
which there was not a clear consensus on pathogenicity from
bioinformatic analysis for further study. The previously reported
R43H mutation was not included in our kinetic analysis as recent
unpublished studies have shown this mutation to be kinetically
inactivating (Nicola Beer, Anna Gloyn unpublished observations)
[35].
Basic kinetic characterisation of the mutant glucokinase proteins
demonstrated that seven of the nine mutations studied were clearly
kinetically inactivating due to either defects in activity or affinity
for glucose. Previous studies have also identified GCK mutations
causal for GCK-MODY which have near normal or paradoxical
kinetics [17,28,29]. In some cases additional functional studies
have demonstrated defects in post-translational regulation by
GKRP and small molecular activators and/or protein and
catalytic stability [28,29,31,36]. We therefore investigated the
effect of the L315H and I436N mutations on the regulation of
glucokinase by its regulatory protein GKRP. Our studies
demonstrated differences in GKRP inhibition of GCK for both
mutations. It has previously been suggested that defects in post-
translational regulation of GCK by GKRP can lead to catalytic
instability which could contribute to the molecular mechanism for
these mutations [36].
Protein instability was assessed using previously validated
thermolability assays and demonstrated that both L315H-GCK
and I436N-GCK displayed marked thermo-instability which could
account for their inactivating properties. Mathematical modeling
incorporating this instability predicted that the threshold for GSIR
would be ,7.0 mmol/L for both mutant proteins, which is in line
with the clinical data. Further studies in a cellular model would be
required to conclusively demonstrate that these mutations results
in protein and/or catalytic instability, but our data, supported by
previous studies, is highly suggestive of defects in catalytic and
protein stability for these two mutants.
For the two proteins N204D-GCK & G258R-GCK for which
kinetic parameters could not be fully determined structural
modeling gave potentialexplanations for the extremely low catalytic
activity of the two mutant proteins. The glucose binding site is
located in the inter domain cleft of the enzyme and is composed of
residues of the large domain (E256, E290), the small domain (T168,
K165) and connecting region II (N204, D205) [37]. Connecting
region II has been proposed to play an important role in the
conformational changes requiredforGCKtomove from itsinactive
to active form [37]. The critical role of residue N204 in the
glucokinasemoleculeisfurthersupported byourstudieswhichshow
a severe impact of mutation at this residue on enzyme kinetics and
additionally by the clinical phenotype of GCK-MODY observed in
the patient with the N204D GCK mutation. Structural analysis of
G258R-GCK, revealed that this mutation also lies in close
proximity to the glucose binding site and that mutation from
glycine to arginine results in occlusion of the glucose binding pocket
and a subsequent spatial barrier for glucose binding.
The minimum prevalence of GCK mutation carriers was
determined as 0.03% of all diabetic patients in Slovakia and is
to date the first estimation of prevalence of GCK-MODY in a
diabetic population. The prevalence of GCK mutation carriers
calculated from an Austrian-German diabetes registry was 0.4%
but this study only included patients under the age of 20 years
[38]. We calculated the minimum prevalence of the GCK-MODY
in Slovakia as 20.0 cases per million which is higher than in two
recent studies from the UK [39,40]. This number is still very likely
to be under estimated since a substantial proportion of cases will
remain undiagnosed as GCK-MODY is largely an asymptomatic
disorder. Shield and colleagues reported 6.4 cases per million with
GCK-MODY [39]. The minimum prevalence of GCK-MODY
determined in Slovakia (one GCK mutation carrier for every 53,
763 inhabitants) is also higher than approximations from Kropff
and colleagues who found among one mutation carrier per 118,
927 inhabitants [40]. The median age of diabetes diagnosis in the
current study was younger than that of the general diabetic
population. Previous work has demonstrated a higher pick up rate
for GCK-MODY in patients diagnosed at a younger age [13,14].
However, since GCK-MODY is often asymptomatic it is likely
that we have still underestimated the prevalence of GCK-MODY
as our study only includes individuals who have been referred by a
Diabetologist for genetic screening. Population studies are
required to accurately determine the prevalence of GCK mutations.
Interestingly, two non-synonymous mutations, L315H and I436N,
have previously been identified only in Czech families, and a
recent study showed that L315H is one of the most prevalent GCK
mutations in the Czech population [41]. This finding could suggest
a potential existence of founder effect in Slovak and Czech
families.
In conclusion, we provide the first evaluation of the prevalence
of GCK-MODY in Slovakia and demonstrate that family,
bioinformatic and functional studies can be used in combination
to assign pathogenicity to missense GCK mutations.
Supporting Information
Figure S1 Pedigrees demonstrating co-segregation data
for GCK mutations with elevated fasting glycaemia for
19/36 probands. Co-segregation data for 3 families with the
271G.C promoter mutation has previously been reported [42].
Squares represent males, circles females, shaded shapes represent
individuals with fasting hyperglycaemia. Fasting plasma glucose
levels (mmol/L) are given in blue underneath each individual.
Symbols shaded ingrey –represent individuals with fasting
hyperglycaemia but with no GCK mutation (phenocopies).
Probands are indicated by an arrow and the letter P. IFG denotes
individuals with impaired fasting glycaemia. NA=not available,
NT=not tested, *=not monitored for IFG or DM. Additional
clinical information on subjects with fasting hyperglycaemia but no
GCK mutations: Family R92 II:3 - lipid profile: cholesterol
8.72 mmol/L (ref. ,5.25), triglycerides 9.62 mmol/L (ref. ,1.7),
HDL-cholesterol 0.82 mmol/L (,1.0). BMI 29.4 kg/m
2; Family
R227 I:2 - BMI 32 kg/m
2, age of diagnosis 62 years, currently
treated with metformin, also treated for hypertension and
dyslipidemia
(TIF)
Figure S2 Structural analysis of wild-type, G258R and
N204D GCK mutants. A The closed (active) crystal structure of
glucokinase (1v4s [37]) is shown in green, with bound-glucose
represented by black spheres and GKA (yellow) bound in allosteric
activator site. B Glucokinase structure zoomed to residue 258,
where wild-type amino acid glycine and mutant arginine is
represented by red and pink respectively. C Glucokinase structure
zoomed to residue 204, with represented side-chain of all amino
acids in polar contact. Wild type amino acid N204 (red) showed
polar bonds (yellow) to amino acids V207 (blue) and A208 (orange)
and 4 solvent molecules (light blue spheres). Mutagenesis to D204
caused a loss of one of two polar bonds of the solvent molecule and
a gain of polar bond (indicated by yellow arrow) with N254 (cyan)
which is located in the neighboring beta sheet.
(TIF)
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